Arctic Bioscience has today released its Annual Report 2022, including the Board of Directors report and financial statements. The report and annual accounts were approved by the Board of Directors after close of business on 28th of March 2023.
The report is attached to this stock notice and is available on the company’s website.
On Thursday 30 March 2023, at 12:00 CET, the Company will host a webcast to present the results an give an operational update. Following the presentation, it will be opened for questions from the audience.
Date: Thursday 30 March 2023
Time: 12:00 CET
Format: Webcast and Q&A
The presentation can be accessed through the Company’s website, or with the link below:
Participants will be required to register to view the webcast and participate in the Q&A.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.
For more information, please contact:
Christer L. Valderhaug
Phone: +47 920 84 601
Jone R. Slinning
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.